EDMONTON, June 6 /CNW/ - Isotechnika Inc. announced today that the
Company received approval from the Polish Competent Authority for
participation in the ongoing Phase 3 European/Canadian clinical trial. This
trial investigates the use of ISA247 in patients suffering from moderate to
severe psoriasis. The Company previously received approval from the German
Competent Authority and Health Canada to commence the trial. At present, a
total of 283 patients have been enrolled in Germany and Canada.
